Andrew D. Goldberg - Net Worth and Insider Trading

Andrew D. Goldberg Net Worth

The estimated net worth of Andrew D. Goldberg is at least $96,885 dollars as of 2024-05-02. Andrew D. Goldberg is the Director of Tarsus Pharmaceuticals Inc and owns about 3,000 shares of Tarsus Pharmaceuticals Inc (TARS) stock worth over $96,885. Details can be seen in Andrew D. Goldberg's Latest Holdings Summary section.

Disclaimer: The insider information is derived from SEC filings. The estimated net worth is based on the assumption that Andrew D. Goldberg has not made any transactions after 2023-12-15 and currently still holds the listed stock(s).

Transaction Summary of Andrew D. Goldberg

To

Andrew D. Goldberg Insider Ownership Reports

Based on ownership reports from SEC filings, as the reporting owner, Andrew D. Goldberg owns 1 companies in total, including Tarsus Pharmaceuticals Inc (TARS) .

Click here to see the complete history of Andrew D. Goldberg’s form 4 insider trades.

Insider Ownership Summary of Andrew D. Goldberg

Ticker Comapny Transaction Date Type of Owner
TARS Tarsus Pharmaceuticals Inc 2023-12-15 director

Andrew D. Goldberg Latest Holdings Summary

Andrew D. Goldberg currently owns a total of 1 stock. Andrew D. Goldberg owns 3,000 shares of Tarsus Pharmaceuticals Inc (TARS) as of December 15, 2023, with a value of $96,885.

Latest Holdings of Andrew D. Goldberg

Ticker Comapny Latest Transaction Date Shares Owned Current Price ($) Current Value ($)
TARS Tarsus Pharmaceuticals Inc 2023-12-15 3,000 32.30 96,885

Holding Weightings of Andrew D. Goldberg


Andrew D. Goldberg Form 4 Trading Tracker

According to the SEC Form 4 filings, Andrew D. Goldberg has made a total of 1 transactions in Tarsus Pharmaceuticals Inc (TARS) over the past 5 years, including 1 buys and 0 sells. The most-recent trade in Tarsus Pharmaceuticals Inc is the acquisition of 1,000 shares on December 15, 2023, which cost Andrew D. Goldberg around $18,960.

Insider Trading History of Andrew D. Goldberg

No transactions are available. GuruFocus only tracks and displays the purchase and sale of non-derivative security in open market or private transactions from SEC filings with the transaction code of P or S.
Total 0
  • 1
Only the transactions in Open Market or Private Sale at the market prices are included. Other transactions such as conversion of derivative security or exercise of options are not included. Insiders are limited to only officers and/or directors of the company.

Andrew D. Goldberg Trading Performance

GuruFocus tracks the stock performance after each of Andrew D. Goldberg's buying transactions within different timeframes. To be detailed, the average return of stocks after 3 months bought by Andrew D. Goldberg is 65.77%. GuruFocus also compares Andrew D. Goldberg's trading performance to market benchmark return within the same time period. The performance of stocks bought by Andrew D. Goldberg within 3 months outperforms 1 times out of 1 transactions in total compared to the return of S&P 500 within the same period.

You can select different timeframes to see how Andrew D. Goldberg's insider trading performs compared to the benchmark.

Please note GuruFocus will not track the insiders’ transaction performance if he/she does not have buying transactions.

Performance of Andrew D. Goldberg

Average Return

No transaction record over 1 Year.

Outperforming Transactions

No transaction record over 1 Year.
Each transaction is measured over a period and compared to .
1 Month 3 Months 6 Months 1 Year 2 Years 3 Years
Return(%) 16.01
Relative Return to S&P 500(%) 14.64

Andrew D. Goldberg Ownership Network

Ownership Network List of Andrew D. Goldberg

No Data

Ownership Network Relation of Andrew D. Goldberg


Andrew D. Goldberg Owned Company Details

What does Tarsus Pharmaceuticals Inc do?

Who are the key executives at Tarsus Pharmaceuticals Inc?

Andrew D. Goldberg is the director of Tarsus Pharmaceuticals Inc. Other key executives at Tarsus Pharmaceuticals Inc include Chief Human Resources Officer Dianne C. Whitfield , director & 10 percent owner & President and CEO Bobak R. Azamian , and Chief Operating Officer Seshadri Neervannan .

Tarsus Pharmaceuticals Inc (TARS) Insider Trades Summary

Over the past 18 months, Andrew D. Goldberg made 1 insider transaction in Tarsus Pharmaceuticals Inc (TARS) with a net purchase of 1,000. Other recent insider transactions involving Tarsus Pharmaceuticals Inc (TARS) include a net sale of 346,867 shares made by Bobak R. Azamian , a net sale of 31,966 shares made by Leonard M. Greenstein , and a net sale of 20,877 shares made by Aziz Mottiwala .

In summary, during the past 3 months, insiders sold 28,810 shares of Tarsus Pharmaceuticals Inc (TARS) in total and bought 0 shares, with a net sale of 28,810 shares. During the past 18 months, 450,842 shares of Tarsus Pharmaceuticals Inc (TARS) were sold and 10,506 shares were bought by its insiders, resulting in a net sale of 440,336 shares.

Tarsus Pharmaceuticals Inc (TARS)'s detailed insider trading history can be found in Insider Trading Tracker table.

To

Tarsus Pharmaceuticals Inc Insider Transactions

No Available Data

Andrew D. Goldberg Mailing Address

Above is the net worth, insider trading, and ownership report for Andrew D. Goldberg. You might contact Andrew D. Goldberg via mailing address: 15440 Laguna Canyon Road, Suite 160, Irvine Ca 92618.

Discussions on Andrew D. Goldberg

No discussions yet.